Katharina Smetanay1,2, Philippe Junio3,4, Manuel Feißt5, Julia Seitz3,4, Jessica Cecile Hassel3,6, Luisa Mayer3,4, Lina Maria Matthies3,4, Arina Schumann3, André Hennigs3,4, Jörg Heil3,4, Christof Sohn3,4, Dirk Jaeger3, Andreas Schneeweiss3,4, Frederik Marmé3,4. 1. National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany. katharina.smetanay@med.uni-heidelberg.de. 2. Department of Obstetrics and Gynecology, University Hospital, Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany. katharina.smetanay@med.uni-heidelberg.de. 3. National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany. 4. Department of Obstetrics and Gynecology, University Hospital, Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany. 5. Institute of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany. 6. Department of Dermatology, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
Abstract
PURPOSE:Chemotherapy-induced alopecia (CIA) is a distressing side effect for women with breast cancer undergoing chemotherapy. Scalp cooling is a method aiming to prevent CIA, but its efficacy is not well defined. Randomized trials until recently and at the time this trial was designed have been lacking. METHODS:Patients undergoing (neo)adjuvant chemotherapy for early breast cancer (EBC) were randomized to scalp cooling (CAP) or observation (NoCAP). All patients received 18-24 weeks of anthracycline- and/or taxane-based chemotherapy. The primary endpoint was patient-reported rate of alopecia according to a modified version of the Dean Scale. Hair preservation was defined as hair loss ≤ grade 2 (≤ 50%). Secondary endpoints were rate of alopecia determined by medical staff, rate of wig/scarf use, tolerability as well as quality of life (QoL). RESULTS:Seventy-nine patients were randomized. Hair preservation was observed in 39.3% of patients in the CAP arm versus 0% in the NoCAP arm (p < 0.001). Wig/scarf use was significantly less frequent in the CAP group (40.7% vs 95.5% outside home before cycle 3, p < 0.001). The drop-out rate was 31.7% and 34.2% in the CAP and NoCAP arm, respectively. Main reasons for drop-out were hair loss, adverse events (CAP), and randomization into control arm. We observed no differences in efficacy between anthracycline-based and non-anthracycline-based regimens. QoL did not differ between the study arms. CONCLUSIONS: This trial adds to the evidence that scalp cooling effectively prevents CIA in a meaningful number of patients. This option should be made available for patients undergoing (neo)adjuvant chemotherapy for EBC.
RCT Entities:
PURPOSE: Chemotherapy-induced alopecia (CIA) is a distressing side effect for women with breast cancer undergoing chemotherapy. Scalp cooling is a method aiming to prevent CIA, but its efficacy is not well defined. Randomized trials until recently and at the time this trial was designed have been lacking. METHODS:Patients undergoing (neo)adjuvant chemotherapy for early breast cancer (EBC) were randomized to scalp cooling (CAP) or observation (NoCAP). All patients received 18-24 weeks of anthracycline- and/or taxane-based chemotherapy. The primary endpoint was patient-reported rate of alopecia according to a modified version of the Dean Scale. Hair preservation was defined as hair loss ≤ grade 2 (≤ 50%). Secondary endpoints were rate of alopecia determined by medical staff, rate of wig/scarf use, tolerability as well as quality of life (QoL). RESULTS: Seventy-nine patients were randomized. Hair preservation was observed in 39.3% of patients in the CAP arm versus 0% in the NoCAP arm (p < 0.001). Wig/scarf use was significantly less frequent in the CAP group (40.7% vs 95.5% outside home before cycle 3, p < 0.001). The drop-out rate was 31.7% and 34.2% in the CAP and NoCAP arm, respectively. Main reasons for drop-out were hair loss, adverse events (CAP), and randomization into control arm. We observed no differences in efficacy between anthracycline-based and non-anthracycline-based regimens. QoL did not differ between the study arms. CONCLUSIONS: This trial adds to the evidence that scalp cooling effectively prevents CIA in a meaningful number of patients. This option should be made available for patients undergoing (neo)adjuvant chemotherapy for EBC.
Entities:
Keywords:
Alopecia; Breast cancer; Chemotherapy; Quality of life; Scalp cooling
Authors: C Paterson; M Kozlovskaia; M Turner; K Strickland; C Roberts; R Ogilvie; G Pranavan; P Craft Journal: J Cancer Surviv Date: 2020-07-18 Impact factor: 4.442
Authors: Cornelia Kolberg-Liedtke; Diana Lüftner; Sara Y Brucker; Wilfried Budach; Carsten Denkert; Peter A Fasching; Renate Haidinger; Nadia Harbeck; Jens Huober; Christian Jackisch; Wolfgang Janni; David Krug; Thorsten Kühn; Sibylle Loibl; Volkmar Müller; Andreas Schneeweiss; Christoph Thomssen; Michael Untch; Marc Thill Journal: Breast Care (Basel) Date: 2022-04-08 Impact factor: 2.268
Authors: Franz-Ferdinand Bitto; Alexander König; Thuy Phan-Brehm; Thomas Vallbracht; Julian Gregor Koch; Timo Schinköthe; Matthias Wolfgarten; Sven Mahner; Nadia Harbeck; Rachel Würstlein Journal: Breast Care (Basel) Date: 2019-07-25 Impact factor: 2.860
Authors: J Bajpai; S Kagwade; A Chandrasekharan; S Dandekar; S Kanan; Y Kembhavi; J Ghosh; S D Banavali; S Gupta Journal: Breast Date: 2019-12-12 Impact factor: 4.380